The role of intestinal CYP2E1 in pathophysiology of the gastrointestinal tract disorders: new therapies for leaky gut syndrome and inflammatory bowel diseases

Read full text Summarise with VIRAT
Authors: Maciej Sałaga, Adam Makaro
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Leaky gut syndrome (LGS) is observed in numerous gastrointestinal (GI) disorders, including inflammatory bowel diseases (IBD) characterized by chronic inflammation affecting the GI tract. It is well-established that the activity of CYP2E1 may contribute to the severity of inflammation due to the production of ROS. The main aim of the project is to evaluate the effect of CYP2E1 inhibitors as potential drugs maintaining intestinal permeability and alleviating intestinal inflammation in vitro and in vivo. Although intestinal CYP2E1 is expressed in rodents and humans, still little is known about its expression in inflamed intestinal tissues. Here, we examined the changes of CYP2E1 level in the gut during inflammation in mice and IBD patients. In in vitro phase, we evaluated the effect of CYP2E1 selective inhibitors on epithelial barrier integrity and inflammation. We verified the hypotheses that treatment with analogs of diallyl sulfide (DAS) protects against increased permeability and ameliorates inflammatory response of Caco-2 cells. In the second phase, we evaluated the influence of selected CYP2E1 inhibitor on epithelial barrier integrity and inflammation in vivo. We used mouse models of: (i) high fructose-induced LGS and inflammation and (ii) dextran sulfate sodium-induced colitis. In the translational part of the project, we used ELISA to examine the expression of CYP2E1 protein in inflamed colon samples from humans. Moreover, we will investigated into potential associations between CYP2E1 level, the expression of proteins involved in intestinal barrier integrity, and selected disease parameters of IBD.

Fields of Study & Subjects

Inflammatory Bowel Disease Gastrointestinal motility and disorders Gut microbiota and health

Publication details

Journal / source
Medical University of Lodz
Publication date
1 January 2026
Language
EN
Document type
Dataset